Comparing intestinal ultrasound with colonoscopy and enterography for people with ulcerative colitis and Crohn's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, observational project will enroll consecutive patients with ulcerative colitis or Crohn's disease who undergo endoscopy at AIG Hospitals. For each patient the study will record diagnostic findings from IBUS, colonoscopy, and enterography when available and will measure the real-world carbon footprint of each pathway including electricity, waste, sterilisation, and patient transportation. The trial will compare diagnostic concordance between IBUS and conventional imaging and quantify emissions differences using on-site data and standard carbon accounting methods. The goal is to determine whether IBUS can reliably inform clinical care with substantially lower environmental impact in routine practice at a tertiary gastroenterology center.

Why it matters

Who can join: the full rules

All consecutive patients undergoing endoscopy procedures with consent for procedures, during the study period will be included

Where it's running

• AIG Hospitals
  Hyderabad, Telangana, India Recruiting
• AIG Hospitals
  Hyderabad, Telangana, India Recruiting

Study contacts

• Study coordinator: Dr.Hardik Rughwani
• Email: dr.hardikr@aighospitals.com
• Phone: 9426928600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stop PPI in active IBD: can you safely go without acid-suppressing meds?

  This study tests whether people with inflammatory bowel disease who have been on proton pump inhibitors can stop taking them and still manage their symptoms.

  Recruiting Phase 4 University of Nottingham · Nottingham · NCT07691138

• Phase 2 testing of new therapies for moderate-to-severe inflammatory bowel disease

  The study will try two experimental medicines, MT-501 and MT-201, to see if they are safe and help adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 Mirador Therapeutics, Inc. · Birmingham, Alabama and 65 other locations · NCT07113522

• Iron treatment for children and young adults with Crohn’s disease and iron deficiency anemia

  This study tests how different iron treatment approaches work for kids and young adults with Crohn’s disease and iron deficiency anemia.

  Recruiting Phase 4 Weill Medical College of Cornell University · New York, New York · NCT07925450

• MGT-006 safety and dosing study for ulcerative colitis

  This study tests an oral microbiome capsule called MGT-006 to see if it is safe and tolerable in adults with moderately active ulcerative colitis, and whether the gut bacteria engraft after treatment.

  Recruiting at 9 sites Phase 1/2 Metagen Therapeutics, Inc. · Naples, Florida and 11 other locations · NCT07913347

• PALI-2108 vs placebo for moderate to severe ulcerative colitis

  A phase 2 study to see if PALI-2108 helps people with moderate to severe ulcerative colitis more than a placebo.

  Recruiting at 28 sites Phase 2 Palisade Bio · Sun City, Arizona and 114 other locations · NCT07845487

• Autologous intestinal organoids applied to Crohn's ulcers in a first-in-human dose-escalation study

  This early-phase study tests a patient-derived intestinal organoid therapy (ATORM-C) delivered during colonoscopy to Crohn’s ulcers to see if it is safe and tolerable and to get a sense of healing.

  Recruiting Phase 1 Organoidsciences LTD. · Seoul · NCT07822087

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.